CORT — Corcept Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $2.38bn
- $2.01bn
- $482.38m
- 93
- 37
- 63
- 69
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 94.2 | 106 | 113 | 101 | 106 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 29 | 36.7 | 50 | 46 | 41.1 |
Other Non-Cash Items | |||||
Changes in Working Capital | -4.69 | -5.36 | -0.057 | 6.02 | 8.22 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Cash from Operating Activities | 136 | 152 | 168 | 120 | 127 |
Capital Expenditures | -1.09 | -1.24 | -0.469 | -0.413 | -0.139 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -117 | -118 | 137 | -114 | 91 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -118 | -119 | 136 | -114 | 90.9 |
Financing Cash Flow Items | -6.09 | -1.07 | -22.8 | -21.7 | -9.11 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -28.6 | 12.2 | -303 | -17.3 | -149 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -10.4 | 44.9 | 1.43 | -11.3 | 69.2 |